Key Takeaways
- 22% revenue growth, 71% EBITDA jump: Strong operational quarter driven by BuLi Chem ramp-up and base business volume gains, despite depressed lithium/bromine pricing and a deliberate pivot away from agrochemicals.
- Battery chemicals guidance slashed again: FY25 target cut to ₹20-30 crore from an earlier ₹50-75 crore, and the FY26 upper end of ₹500 crore is now "under review" as customer ramp-ups keep slipping to the right.
- The giga-factory thesis is intact but the clock is ticking: One major ACC customer is in trial production, a second starts in H2, and Neogen's salt quality milestone is met, yet meaningful volume is still 12-18 months away and the "pain period" extends through 2026.
- Standalone business is carrying the load: FY26 revenue guidance of ₹950-1,000 crore is reaffirmed, with pharma, organolithium and bromine derivatives offsetting agro weakness and the advanced intermediates drag from Chinese dumping.
- What to watch next quarter: Whether the international salt customer audit converts to commercial orders in Q1, the pace of the domestic giga-factory ramp beyond trial production, and any revision to the FY26 battery chemicals number.
Battery Chemicals: The Waiting Game
- Giga-customer reality check: One major ACC manufacturer is already in trial production and taking Neogen's electrolyte, with ramp-up to closer to giga scale expected by end of Q4 or early Q1. A second giga factory is expected to start in H2 of the calendar year.
- The capacity math is compelling but front-loaded with risk: A single customer can fill 25-50% of Neogen's planned capacity, meaning the revenue curve will be lumpy and binary, not gradual. Each new factory start gives one discrete bump in sales volume.
- Salt quality milestone achieved, now waiting on the customer: Neogen met the most stringent international quality requirement for electrolyte salts, a first-time effort that took longer than expected. Production data has been shared; the customer is evaluating and must restart its qualification process for any process change.
- International salt sales hinge on one audit: Customer audit and sample approval are expected in Q4 or maximum by early Q1, after which international customers, who are already buying from China and want to switch, can begin purchasing.
- Dahej as a flexible starter plant: The 400 MT salt and 2,000 MT electrolyte capacity at Dahej is now shipping trial and approved material, serving as a startup facility for smaller initial volumes while Pakhajan is built for full-scale operations.
- Pakhajan on track but approval is a fresh cycle: Trial production is expected by end of 2026. Electrolyte approval may be faster because existing domestic customers will graduate from the current site, but salt will require a new, separate approval process.
- FY28-FY29 is the real prize: Management expects full utilisation of the electrolyte plant by FY28 or FY29, with 30 GWh capacity fillable by 6-7 customers at 10 GWh-plus volumes. The intervening period, 2025 and 2026, is explicitly called a "pain period."
Dr. Harin Kanani: "I think we will have some pain in 2025 and 2026, but I think second half of 2026-27 onwards we should be good and with the giga factories which are coming and the position in which Neogen is, we are quite confident to achieve…FY28 or FY29, the guidance which we have given for full utilisation of our electrolyte plant."
Standalone Business: The Here and Now
- FY26 revenue guidance reaffirmed at ₹950-1,000 crore: Confidence rests on pharma improvement, good organolithium demand, bromine derivatives performance, and an agro recovery that is just beginning to contribute.
- Organic-inorganic divergence tells the pricing story: Organic revenue grew 36% while inorganic revenue declined 29%, driven entirely by the sharp fall in bromine and lithium raw material prices. Volume gains are real; price headwinds mask them.
- Agrochemical pivot is working: The company deliberately shifted from agrochemicals to semiconductors, flavours and fragrance, and select industrial custom synthesis manufacturing, mitigating the sector slowdown. Agro has only just started contributing in Q3, with more expected.
- CSM business broadening: The 12-15% custom synthesis manufacturing segment now spans agro, pharma, flavour and fragrances, industrial and semiconductor. Many are trial productions from this year and prior; stabilisation is expected next year, with CSM contributing 15-20% of overall revenue.
- Advanced intermediates is the one sore spot: This segment is under pressure from low Chinese API and intermediate prices being dumped in India, making it the only area of concern in the standalone portfolio.
- BuLi Chem is firing on all cylinders: The merger is now effective, the business is at full utilisation, and Center plus Environmental Clearance for capacity doubling is in hand, awaiting only local approval. Revenue next year could be closer to or exceed ₹100 crore with very small CAPEX.
- Bromo derivatives share has halved: Down from ~20% to 10-12% of revenue due to Chinese dumping at the API and intermediate level. Organolithium is slightly above 5% and could exceed 10%. Inorganic lithium sits at 15-20%.
Margins, Costs & Operational Levers
- 71% EBITDA growth on operating leverage: Improved plant utilisation, operational efficiency and lower employee cost drove the jump, with PAT of ₹10 crore also helped by a favourable base effect from one-time expenses in Q3 last year.
- Other expenses rose QoQ for seasonal reasons: A ~₹7 crore increase was driven by Diwali bonuses, major exhibitions and some one-time items, a pattern that also appeared in the prior year.
- Pass-through pricing protects absolute EBITDA: Contracts have raw material price pass-through, so per-kg or per-dollar contribution does not change with lithium price swings. Management's focus is absolute EBITDA and ROCE, not margin percentages that fluctuate with input costs.
- Cash flow and working capital improved but details are withheld: Management declined to disclose 9-month cash flow from operations or inventory levels, stating only that both have "substantially improved" and are "very much in line with guidance."
The Localisation Moat
- China-plus-one is real, even with predatory pricing: International customers importing small volumes from China or Korea face hidden logistics costs, container return costs, risk of material degradation, cell performance issues, and the difficulty of discarding bad electrolyte. Most see clear value in a local supplier once those costs are factored in.
- The customs duty overhang helps: Expected duties beyond 2026, combined with logistics costs, make the localisation case compelling even before factoring in supply security. The government's intent is clear through the PLI scheme, and BIS standards plus duties are expected once domestic cell production begins.
- Supply security is a standalone driver: International customers, regardless of IRA policy, want an alternative because they cannot depend 95% on China. This is an independent demand driver beyond price competitiveness.
- Some customers lack electrolyte recipes: Certain smaller players do not have their own electrolyte formulations and are forced to buy from international suppliers in very small quantities, creating an additional opening for Neogen's bundled offering.
- OEMs are internalising battery production: Tata has Agratas, Ola has a Gigafactory. Batteries are the new engines of vehicles, and OEMs want to internalise for strategic, innovation and design reasons. These customers prefer pass-through pricing models on material cost, focusing on conversion cost efficiency.
Dr. Harin Kanani: "Already China is doing predatory pricing, but when we look at our 30 KTA and we look at China, then we look at further logistic costs in bringing those containers, and sending them back. And then if you further factor in customs duties which are expected to come in beyond 2026. So, I think when you factor all of that in, most customers can clearly see value in a local supplier."
Lithium Price & Raw Material Dynamics
- Current lithium prices are unsustainable: Management expects steady-state lithium carbonate/hydroxide prices between $15-$25 per kg, averaging $20. At current levels, the majority of new miners cannot make money, and if the situation persists, production cuts will create another supply-side shock.
- Pass-through pricing beats spot over a cycle: Management's analysis shows that over a four-year horizon, pass-through pricing saves the customer money versus spot because "the crazy highs more than make up for the crazy lows." Customers with internal cell consumption prefer this model.
- CAPEX is insulated from price swings: The investment plan does not change with lithium price fluctuation except for working capital adjustment. The absolute EBITDA or margin target remains the same regardless of where input prices settle.
Dr. Harin Kanani: "The current price is not sustainable because majority of the new miners are not able to make money. So, if the situation doesn't change, you know, they will stop production and then you will have another supply side shock."
Capacity Build-Out & Approvals
- Salt capacity stepping up in phases: Existing 400 MTPA will fully contribute from Q1, maximum by Q2 next year. The remaining capacity up to 2,500 tonnes comes online in phases by June and September 2025, then expands to 5,500 tonnes by end of next financial year.
- Pakhajan greenfield is on schedule: Full financial closure achieved, 70% civil and design work completed, modular plant development underway at the international partner, and key equipment expected from MEC by H2 of calendar 2025. Commercial production is on track for FY26.
- BuLi capacity doubling is low-hanging fruit: Center permission and Environmental Clearance received, local approval awaited. The expansion requires very small CAPEX and will enable growth in the next financial year.
- Patancheru CAPEX under discussion: The company is considering capacity increases and discussing internally with customers; details will be shared once the board approves. Dahej and Karakhadi are seeing only debottlenecking or specific equipment additions, not major CAPEX.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Standalone revenue | ₹950 to ₹1,000 crore | FY26 |
| Battery chemicals revenue (current year) | ₹20-30 crore (revised down from ₹50-75 crore) | FY25 |
| Battery chemicals revenue (next year) | Upper end ₹500 crore, but "under review" | FY26 |
| International salt customer audit and approval | Audit and sample approval expected; commercial sales commence thereafter | Q4 FY25 or maximum early Q1 FY26 |
| Domestic giga-factory ramp-up | Ramp to closer to giga scale | End of Q4 FY25 or early Q1 FY26 |
| Second giga factory start | Operations begin | H2 of calendar 2025 |
| Existing salt capacity (400 MTPA) full contribution | Full volume contribution | Q1, maximum Q2 FY26 |
| Salt capacity expansion to 2,500 tonnes | Phased commissioning | June and September 2025 |
| Salt capacity expansion to 5,500 tonnes | Full capacity available | End of FY26 |
| BuLi capacity doubling | Doubling with very small CAPEX, subject to local approval | Next financial year |
| BuLi revenue | Closer to or exceeding ₹100 crore | FY26 |
| Pakhajan commercial production | Start of commercial production | FY26 |
| Pakhajan trial production | Trial production begins | End of 2026 |
| Full electrolyte plant utilisation | 30 GWh capacity filled | FY28 or FY29 |
| CSM contribution to overall revenue | 15% to 20% | Next year |
Key Metrics
| Metric | Q3 FY25 |
|---|---|
| Revenue | ₹201 crore, 22% growth YoY |
| Organic revenue | ₹177 crore, 36% increase YoY |
| Inorganic revenue | ₹24 crore, 29% decline YoY |
| EBITDA | ₹34.6 crore, 71% growth YoY |
| EBITDA margin | 17.2%, consolidated |
| Profit After Tax | ₹10 crore |
| Organic revenue impact from raw material price decline | ₹34 crore higher would have been recorded in Q3 FY25, adjusting for bromine and lithium price fall |
| Inorganic revenue impact from raw material price decline | ₹13 crore higher would have been recorded in Q3 FY25, adjusting for bromine and lithium price fall |
| FY26 standalone revenue guidance | ₹950 to ₹1,000 crore |
| Battery chemicals revenue guidance for FY25 | ₹20 to ₹30 crore, revised from earlier expectation of ₹50 to ₹75 crore |
| Battery chemicals revenue YTD | More than ₹10 crore, double digits |
| CSM business contribution | ~14% of overall revenue, fluctuated between 12% to 15% during FY25 |
| BuLi Chem EBITDA margin | ~18%, plus or minus 1% to 1.5% |
| Total CAPEX envisaged | ₹1,500 crore |
| CAPEX deployed till Q3 FY25 | ~₹419 crore |
| Standalone debt | Close to ₹450 crore |
| Lithium electrolyte salts and additives capacity at Dahej | 400 MTPA, expanding to 2,500 MTPA by next financial year and 5,500 MTPA by end of next financial year |
| Electrolyte capacity at Dahej | 2,000 MTPA |
| Greenfield battery materials facility civil work completion | 70% |
| Giga factories expected by end of 2026 | At least 5, with capacities between 5 GWh to 30 GWh |
| Active international customers for electrolyte salts | 4 to 5, out of more than 20 to 25 engaged globally |
| Battery chemicals revenue band for FY26 (Neogen Ionics) | ₹300 to ₹500 crore, upper end under review |